Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Rosner, F.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

LETTER

Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia

right arrow Fred Rosner, MD

1 November 1996 | Volume 125 Issue 9 | Page 780


TO THE EDITOR:

I question the propriety of bone marrow transplantation in patients with chronic lymphocytic leukemia (CLL) in Rai stages 0, 1, or 2 who may be asymptomatic for years without any specific treatment. As reported by Michallet and colleagues [1], 23 of the 54 transplant recipients had disease in Rai stage 0, 1, and 2 at the time of transplantation. Nonetheless, 25 (46%) died of treatment-related complications. How can one justify such a risk–benefit ratio? Although Rai stage 3 or 4 disease is associated with a relatively short median survival, this is not the case for early-stage CLL, in which the prognosis is often good for many years. Michallet and colleagues' Table 1 indicates that 10 of the 23 patients with Rai stage 0, 1, and 2 disease died of complications related to bone marrow transplantation, an unacceptably high mortality rate for a disease that is otherwise indolent until it reaches stage 3 or 4.

What type of informed consent was obtained from these patients? Were they apprised of the possible lethality of bone marrow transplantation? Did the ethics committees at the various institutions approve of this procedure for patients with early-stage CCL? I am deeply troubled by the report of Michallet and colleagues and somewhat surprised that these concerns were not raised by the reviewers of the manuscript or by the editors of Annals.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowREFERENCE

Mt. Sinai School of Medicine New York, NY 10029.


REFERENCE
space
up arrowTop
up arrowAuthor & Article Info
dotREFERENCE

1. Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med. 1996; 124:311-5.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.




This article has been cited by other articles:


Home page
Am Soc Clin Oncol Ed BookHome page
J. G. Gribben
The Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia
ASCO Educational Book, January 1, 2008; 2008(1): 291 - 296.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. J. Hlubocky, M. J. Ratain, M. Wen, and C. K. Daugherty
Complementary and Alternative Medicine Among Advanced Cancer Patients Enrolled on Phase I Trials: A Study of Prognosis, Quality of Life, and Preferences for Decision Making
J. Clin. Oncol., February 10, 2007; 25(5): 548 - 554.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. R. Muller, G. Tsakou, F. Grunebach, S. M. Schmidt, and P. Brossart
Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells
Blood, March 1, 2004; 103(5): 1763 - 1769.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Markman
Safety Issues in Using Complementary and Alternative Medicine
J. Clin. Oncol., September 15, 2002; 20(90001): 39s - 41.
[Abstract] [Full Text] [PDF]


Home page
Arch Fam MedHome page
C. C. Gotay and D. Dumitriu
Health Food Store Recommendations for Breast Cancer Patients
Arch Fam Med, August 1, 2000; 9(8): 692 - 698.
[Abstract] [Full Text] [PDF]


box Article
 arrow  Table of Contents                
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Rosner, F.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online